To improve upon the non-invasive detection of BCa by further validating a multiplex ELISA
assay directed at a BCa-associated diagnostic signature in voided urine samples of
patients with gross hematuria.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03193528.
Locations matching your search criteria
United States
Texas
Dallas
UT Southwestern/Simmons Cancer Center-DallasStatus: Active
Contact: Yair Lotan
Phone: 214-648-0389
Hematuria is the most common presentation of BCa with 22% of patients with gross
hematuria harboring BCa. VUC is the most widely used urine-based assay for detecting BCa;
however, it fails to detect approximately 50% of low-grade or early stage BCa when it is
most curable.
Because of this severe limitation, patients with hematuria (microscopic or gross) will
undergo an invasive examination of the urinary bladder, where a miniature camera is
inserted into the bladder. We propose to improve upon the non-invasive detection of BCa
by further validating a multiplex ELISA assay directed at a BCa-associated diagnostic
signature in voided urine samples of patients with gross hematuria.
Trial PhaseNo phase specified
Trial TypeNot provided by clinicaltrials.gov
Lead OrganizationCedars Sinai Medical Center
